Cellcyte Genetics (SHPN) Inactive 10-Q2010 Q1 Quarterly report

Filed: 24 May 10, 12:00am

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigious
Readability	H.S. freshman Avg

New words: attempt, award, bearing, begun, behalf, codified, comply, contemplated, Contemplation, conventional, correct, delinquent, discount, dismissed, holder, Improving, increase, Lending, loaned, Mutual, percent, permitted, prejudice, Release, remediation, repayment, restart, roll, settled, storage, underlying, unsecured

Removed: accountant, acquisition, active, Administration, adverse, arbitrate, asserting, audit, beneficial, Bothell, breach, certified, charge, claim, commenced, commencement, consent, coverage, decrease, decree, dedicated, default, defend, defending, demand, denying, Department, director, disputing, enabling, endeavor, external, finance, focused, formal, formalized, GAAP, hierarchy, imminently, individually, informal, injected, injunctive, inquiry, invested, investigate, investigation, June, lack, learned, licensed, localize, measuring, merit, nongovernmental, notice, notified, operate, ordered, organ, patented, payable, pending, perform, produce, proprietary, quoted, receive, relating, rent, requested, resolving, respond, scientific, September, suspension, target, targeting, tenant, testing, theory, threatened, unpaid, VA, valid, Veteran, view, vigorously, withheld, wrongdoing

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

SHPN similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 32.1

CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER

PURSUANT TO

18 U.S.C. SECTION 1350

The undersigned, John M. Fluke, Jr., the Interim Principal Executive Officer of CellCyte Genetics Corporation, hereby certifies, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to his knowledge, the Quarterly Report on Form 10-Q of CellCyte Genetics Corporation, for the quarterly period ended March 31, 2010, fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, and that the information contained in the Quarterly Report on Form 10-Q fairly presents in all material respects the financial condition and results of operations of CellCyte Genetics Corporation.

Date:

May 20, 2010.


	/s/ “John M. Fluke, Jr.”___
	John M. Fluke, Jr. Interim Principal Executive Officer

__________

Exhibit 32.2

CERTIFICATION OF PRINCIPAL ACCOUNTING OFFICER

PURSUANT TO

18 U.S.C. SECTION 1350

The undersigned, Randy A. Lieber, the Principal Accounting Officer of CellCyte Genetics Corporation, hereby certifies, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to his knowledge, the Quarterly Report on Form 10-Q of CellCyte Genetics Corporation, for the quarterly period ended March 31, 2010, fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, and that the information contained in the Quarterly Report on Form 10-Q fairly presents in all material respects the financial condition and results of operations of CellCyte Genetics Corporation.

Date:

May 20, 2010.


	/s/ “Randy A. Lieber”___
	Randy A. Lieber Principal Accounting Officer

__________

We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.